Antineoplastic Agents: Cytotoxic Agents: Mitotic Inhibitors
ITAXO4 “Taxotere injection” 20 mg/ml; 1 ml/vial
INOLB1 “Nolbaxol injection”” 20 mg/ml; 1 ml/vial
適應症：乳癌、非小細胞肺癌、前列腺癌、頭頸癌、胃腺癌。
Usual dose:
Breast cancer (monotherapy): 60-100 mg/m2 IV over 1 h q3w; (combination therapy): 75 mg/m2 IV q3w with capecitabine.
Breast cancer, operable node-positive (adjuvant): 75 mg/m2 IV 1 h after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 q3w for 6 courses.
Lung cancer, non-small cell (monotherapy): 75 mg/m2 IV over 1 h q3w; (combination therapy): 75 mg/m2 IV over 1 h followed by cisplatin 75 mg/m2 IV over 30-60 min q3w.
Dose adjustment:
Hepatic impairment: p’ts with bilirubin > the upper limit of normal (ULN) should generally m2 not receive docetaxel; p’ts with serum glutamic-oxaloacetic transaminase and/or serum glutamic pyruvic transaminase >1.5× ULN concomitant with alkaline phosphatase > 2.5× ULN should generally not receive docetaxel.
Adverse effect:
Common: alopecia, asthenia, neuropathy, diarrhea, N/V, stomatitis, fever in the absence of infection and allergy, fluid retention.
Serious: edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, colitis, anemia (< 8 g/dL), febrile neutropenia, leukopenia (<1000 cells/mm3), neutropenia (< 500 cells/mm3), thrombocytopenia, hepatotoxicity, anaphylaxis, infectious disease.
健保使用規範：
（87/7/1、92/11/1、93/8/1、95/8/1、96/1/1、99/6/1、100/1/1、101/9/1）
- 乳癌：
(1)局部晚期或轉移性乳癌。
(2)與anthracycline合併使用於腋下淋巴結轉移之早期乳癌之術後輔助性化學治療。(99/6/1)
(3)早期乳癌手術後，經診斷為三陰性反應且無淋巴轉移的病人，得作為與cyclophosphamide併用doxorubicin的化學輔助療法。(101/9/1）
- 非小細胞肺癌：局部晚期或轉移性非小細胞肺癌。
- 前列腺癌：於荷爾蒙治療失敗之轉移性前列腺癌。
- 頭頸癌：限局部晚期且無遠端轉移之頭頸部鱗狀細胞癌且無法手術切除者，與cisplatin及5-fluorouracil併用，作為放射治療前的引導治療，限使用4個療程。(100/1/1)